CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025

Key takeaways

CRSP is trading around $56 per share after an 8.5% surge on December 3; the stock sits roughly mid‑range between its 52‑week low of about $30 and high near $78. ^[1]
CASGEVY, the first FDA‑approved CRISPR gene‑editing therapy, is commercially launched for sickle cell disease and transfusion‑dependent beta‑thalassemia across the U.S., Europe, and multiple Middle Eastern markets, but revenue ramp so far is slower than early hype. ^[2]
New in‑vivo program CTX310 just delivered breakthrough Phase 1 results, cutting LDL cholesterol and triglycerides by around 50% with a one‑time CRISPR infusion, and up to ~80% in company data — a potential shift from rare diseases to mass‑market cardiovascular risk. ^[3]
Q3 2025 showed a deep loss but a big cash pile: $0.9M in revenue, a $106M net loss, yet roughly $1.9B in cash and marketable securities, giving CRISPR Therapeutics a multi‑year runway. ^[4]
Takeover rumors are swirling, with multiple reports suggesting a large U.S. pharma (market cap $100–$200B) has hired advisers to explore a bid — but no official offer or named suitor so far. ^[5]
Wall Street largely sees upside: consensus 12‑month price targets cluster around the high‑$60s to mid‑$70s, implying roughly 20–35% potential upside from current levels, but with targets scattered from the low $30s up to $120. ^[6]

CRISPR Therapeutics stock today: price, volatility and positioning

As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. ^[7]

Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. ^[8]

A few quick stats:

Market cap: roughly $5.9 billion
Trailing EPS: around –$5.6 per share, i.e. the company is firmly unprofitable ^[9]
Volatility: average daily moves around 5–10%; Investor’s Business Daily recently gave CRSP a Relative Strength (RS) Rating of 80, putting it among the better‑performing stocks over the past year. ^[10]
Short interest: algorithmic analysis from Intellectia estimates a short‑sale ratio around 26% of recent trading volume as of December 2, 2025, highlighting how polarizing the name has become. ^[11]

Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong Buy candidate” near term but expects a lower average price by 2026 and 2030. ^[12]

Translation: this is a high‑beta biotech that can easily move 5–10% in a day on news, rumors, or a badly worded slide in a conference deck.

CASGEVY: first commercial CRISPR therapy, slow but important launch

Why CASGEVY matters

CRISPR Therapeutics’ first commercial product, CASGEVY™ (exagamglogene autotemcel, exa‑cel), sits at the center of the story.

In December 2023, the U.S. FDA approved CASGEVY for sickle cell disease (SCD) in patients 12+ with recurrent vaso‑occlusive crises — the first FDA‑approved therapy using CRISPR/Cas9 gene editing. ^[13]
In January 2024, CASGEVY was also approved in the U.S. for transfusion‑dependent beta‑thalassemia (TDT), again as a one‑time ex vivo CRISPR edit of a patient’s own stem cells. ^[14]

In clinical trials, the majority of treated SCD patients had no severe sickle crises for at least 12 months after infusion, and most TDT patients became transfusion‑independent — essentially a functional cure for many, at least over the follow‑up period so far. ^[15]

Mechanistically, CASGEVY edits a regulatory region of the BCL11A gene in hematopoietic stem cells to reactivate fetal hemoglobin (HbF), which prevents red blood cells from sickling. ^[16]

Where it’s approved and how the launch is going

By CRISPR’s Q2 2025 update, CASGEVY had become a truly global product, approved (for SCD and/or TDT) in:

United States, Great Britain, European Union, Saudi Arabia, Bahrain, Qatar, Canada, Switzerland and the United Arab Emirates, with reimbursement deals in at least 10 countries. ^[17]

Commercial rollout metrics, though, show how hard it is to deliver a one‑and‑done gene‑edited transplant in the real world:

As of June 30, 2025, CRISPR reported >75 authorized treatment centers (ATCs) activated globally, ~115 patients who had completed first cell collection, and 29 patients infused with CASGEVY. ^[18]
A later analysis summarizing the company’s Q3 2025 update suggests those figures had risen to ~165 cell collections and 39 infusions by September 2025. ^[19]

Vertex Pharmaceuticals, which leads manufacturing and commercialization and splits costs and profits 60/40 with CRISPR Therapeutics, has reported modest but growing revenue:

Q2 2025 CASGEVY sales of about $30.4M, with guidance for > $100M in revenue for full‑year 2025. ^[20]

Given per‑patient pricing around $2.2 million in the U.S., even small changes in uptake translate into large revenue swings. ^[21]

Analysts increasingly describe CASGEVY as clinically spectacular but commercially slower‑than‑hoped: patient eligibility, intensive chemotherapy conditioning, fertility concerns, payer negotiations and manufacturing logistics all constrain speed of adoption. ^[22]

For CRISPR shareholders, CASGEVY is both proof that the platform works in people and a reminder that executing on ultra‑complex therapies is a marathon, not a meme spike.

Q3 2025: deep losses, but a huge cash cushion

CRISPR’s Q3 2025 Form 10‑Q paints the classic late‑stage biotech picture: big spending, little top line, chunky runway. ^[23]

Key numbers for the quarter ended September 30, 2025:

Revenue:$0.9M, almost entirely from grants (profit share from CASGEVY is still handled through collaboration accounting).
Operating expenses:$132.9M, including
- $58.9M in R&D
- $57.1M in collaboration expenses (driven largely by sharing CASGEVY costs with Vertex)
Net loss:$106.4M, or –$1.17 per share
Year‑to‑date net loss:$451M, inflated by about $96M of in‑process R&D tied to the Sirius Therapeutics siRNA collaboration.
Liquidity:
- $286.5M in cash and equivalents
- $1.63B in current marketable securities
- plus $28.4M in non‑current securities — almost $1.95B in highly liquid assets.
The company also sold 5.1M shares via its 2021 at‑the‑market (ATM) program, raising about $286.8M, and has since launched a new 2025 ATM. ^[24]

Third‑party fundamental analysis notes:

Revenues around $35M on a trailing basis and net margins below –1,300%, reflecting just how early commercialisation still is.
Yet balance‑sheet metrics like an Altman Z‑Score of ~8.4 and very low debt suggest no near‑term solvency risk, while a cash ratio >16x underscores how cash‑rich the company is relative to liabilities. ^[25]

Underneath the alphabet soup: CRISPR is spending aggressively on late‑stage and next‑generation programs, losing hundreds of millions per year, but has years of runway at its current burn — a key enabler for swinging at big, risky indications.

CTX310 and the in‑vivo pipeline: from rare disease to mass‑market cardio?

If CASGEVY proves CRISPR can cure rare genetic diseases, CTX310 is the bet that CRISPR can reshape common cardiovascular disease.

CTX310: one‑shot CRISPR for cholesterol and triglycerides

CTX310 is an in‑vivo CRISPR/Cas9 therapy delivered via lipid nanoparticles (tiny fat bubbles) to the liver, targeting the ANGPTL3 gene. Loss‑of‑function variants in ANGPTL3 are naturally associated with low LDL cholesterol and triglycerides and reduced cardiovascular risk, without obvious health downsides. ^[26]

2025 has been a big year for CTX310:

In a Phase 1 trial across the UK, Australia and New Zealand, 15 patients with uncontrolled LDL cholesterol and triglycerides received a single IV infusion of CTX310.
A Wired‑covered analysis of the trial reported that the highest dose cut LDL and triglycerides by about 50% on average within two weeks, with the effect persisting for at least 60 days, the duration of the study. ^[27]
CRISPR’s own Q2 2025 update and subsequent investor commentary highlighted dose‑dependent reductions up to ~82% in triglycerides and 86% in LDL in ongoing dose‑finding, with no clinically meaningful liver enzyme elevations. ^[28]
Safety so far looks acceptable: a few transient infusion‑related symptoms, one patient death in the lowest‑dose cohort attributed to pre‑existing severe heart disease rather than the therapy itself, and long‑term 15‑year follow‑up planned as per gene‑therapy norms. ^[29]

The Phase 1 results were presented as a late‑breaking trial at the American Heart Association (AHA) Scientific Sessions 2025 and simultaneously published in The New England Journal of Medicine, signalling serious scientific cred. ^[30]

CRISPR is now moving CTX310 into Phase 1b cohorts in severe hypertriglyceridemia and mixed dyslipidemia and is guiding to Phase 2 trials in 2026, positioning the therapy initially for very high‑risk patients before potentially moving earlier in the disease spectrum. ^[31]

If CTX310 (or a follow‑on) can deliver durable, one‑shot LDL/TG lowering with an acceptable safety profile, the addressable population balloons from tens of thousands (SCD/TDT) to tens of millions of cardiovascular patients — which is why some analysts refer to CTX310 as a “de‑risking catalyst” for CRISPR’s long‑term equity story. ^[32]

CTX320, CTX340, CTX450 and CTX460: a full in‑vivo toolkit

CTX310 isn’t a one‑off; it’s the lead in a small army of in‑vivo programs:

CTX320 targets the LPA gene to lower lipoprotein(a), a genetically driven cardiovascular risk factor affecting up to 20% of the global population. A Phase 1 trial is underway, with an update expected in the first half of 2026. ^[33]
CTX340 uses in‑vivo editing of angiotensinogen (AGT) for refractory hypertension; CRISPR has flagged a first clinical poster at AHA 2025 and is positioning it for patients whose blood pressure remains uncontrolled despite multiple drugs. ^[34]
CTX450 targets ALAS1 in liver for acute hepatic porphyria, a rare but nasty liver disorder; both CTX340 and CTX450 are in IND/CTA‑enabling studies. ^[35]
CTX460, unveiled in 2025, is a SyNTAX™/SyNTase™‑based in‑vivo edit for alpha‑1 antitrypsin deficiency (AATD). Preclinical data presented at ESGCT showed >90% mRNA correction and roughly five‑fold increases in serum AAT in animal models, with human trials targeted around 2026. TS2 Tech

In short: CRISPR is trying to evolve from “a CASGEVY royalty stub” into a platform cardio‑metabolic company, using the same gene‑editing machinery that fixed rare blood diseases to tackle very common chronic conditions.

CAR‑T, autoimmune disease and regenerative medicine

Beyond hemoglobinopathies and cardiometabolic disease, CRISPR Therapeutics is also pushing CRISPR‑edited cell therapies into oncology, autoimmunity and diabetes:

CTX112 (CD19 allogeneic CAR‑T):
- Being tested in relapsed/refractory B‑cell malignancies and autoimmune diseases (including systemic lupus erythematosus, systemic sclerosis and inflammatory myositis). ^[36]
- Received Regenerative Medicine Advanced Therapy (RMAT) designation for certain lymphoma indications based on early data. ^[37]
CTX131 (CD70 allogeneic CAR‑T):
- In trials for solid tumors and hematologic malignancies, with further updates guided for 2025. ^[38]
Type 1 diabetes / CTX211:
- A gene‑edited allogeneic beta‑cell program aiming to provide insulin‑producing cells without chronic immunosuppression; CRISPR has signaled additional updates in 2025. ^[39]
SRSD107 siRNA (FXI):
- A long‑acting siRNA for thrombosis prevention, co‑developed with Sirius Therapeutics. The EMA has already authorized a Phase 2 trial in patients undergoing knee replacement surgery. ^[40]

That’s quite a bit of alphabet, but the gist is simple: CASGEVY may have opened the door, yet the equity value increasingly rests on an entire multi‑asset platform, not a single product.

Takeover speculation: real bid or just biotech fan‑fiction?

In the back half of 2025, CRISPR Therapeutics quietly migrated from “gene‑editing pure play” to “possible M&A target” in market chatter.

Several outlets — including GuruFocus, Seeking Alpha, Yahoo Finance and StockJabber — have reported unconfirmed rumors that a large U.S. biopharma company with a $100–$200B market cap is exploring a bid for CRISPR Therapeutics, allegedly working with top law firm Skadden, Arps and external advisers. ^[41]

Key points from those reports and analyses:

No bidder has been named, and no formal offer has been announced.
The logic of a deal is straightforward on paper:
- CASGEVY royalties and profit‑share with Vertex
- A potentially blockbuster in‑vivo asset in CTX310
- A well‑funded, diversified pipeline
CRISPR’s own fundamentals — including ~$1.9B in cash and securities, low debt, and a market cap near $5–6B — make it digestible for a big pharma balance sheet. ^[42]

At the same time, M&A rumor cycles are basically a fundamental force of nature in biotech. Most don’t end in an actual transaction, and when they do, the price is often less dramatic than the most bullish notes in the rumor mill.

For now, the takeover chatter mainly adds optionality and volatility:

Short‑term traders bid the stock up on each new “whisper”.
Long‑term investors have to decide whether potential M&A is a central part of their thesis or just a pleasant, noisy side quest.

Who owns CRSP? Institutions, Cathie Wood…and the shorts

Ownership data and fund moves give a sense of who’s actually betting on CRISPR Therapeutics.

Institutional ownership is high — GuruFocus pegs it around 78%, with insiders owning under 2% and having sold roughly 56,000 shares over the last three months. ^[43]
Recent 13F filings show firms like Rhumbline Advisers and Legal & General Group initiating or increasing stakes in CRSP, according to MarketBeat’s December 4, 2025 alerts. ^[44]
Finviz/InsiderMonkey data highlight CRISPR Therapeutics as a top‑10 holding in Cathie Wood’s ARK Invest, representing roughly 3.8% of ARK’s portfolio, worth over $600M, even after ARK modestly trimmed its position in 2025. ^[45]
On the other side of the trade, Intellectia’s numbers show short‑sale activity around 26% of recent volume, a sign that many traders are actively betting against the stock. ^[46]

So you have a gene‑editing company:

loved by high‑conviction innovation funds,
widely owned by institutions,
heavily shorted,
and rumored to be a takeover target.

Cue the volatility.

Wall Street forecasts: plenty of upside, massive disagreement

Depending on which dataset you look at, between 21 and nearly 40 analysts now cover CRISPR Therapeutics.

Conventional analyst targets

A quick tour of the aggregators:

MarketBeat (21 analysts, last 12 months):
- Consensus rating: Hold (11 Buy, 8 Hold, 2 Sell)
- Average 12‑month price target:$67.42
- Range:$9 – $120
- Implied upside from ~$56: ~20%. ^[47]
StockAnalysis:
- Consensus rating: Buy
- Average target:$71.5
- Range:$31.6 – $120
- Implied upside: ~28%. ^[48]
Benzinga (26 analysts):
- Consensus rating: Buy
- Consensus target:$71.57, with a high of $120 (Truist) and low of $30 (TD Cowen).
- The three most recent calls (Chardan, Citi, RBC) average around $67 in price targets. ^[49]
TickerNerd‑tracked data (38 analysts):
- 1 Sell, 10 Hold, 17 Buy, 10 Strong Buy
- Median target: about $76, implying ~36% upside. ^[50]
GuruFocus’s model assigns a target around $78.4 and a recommendation score of 2.2, also roughly in “Buyish Hold” territory. ^[51]

If you average the averages, Wall Street roughly says:

“We think CRSP is worth 20–35% more than it trades for today, but we disagree wildly on how that plays out.”

The spread from single‑digit targets to $120 reflects deep uncertainty about:

how fast CASGEVY scales,
how regulators and payers treat ultra‑expensive gene therapies, and
whether CTX310’s early data can translate into a large, durable commercial franchise.

Quant and technical models

Quant‑driven sites add their own spice:

StockInvest.us calls CRSP a “hold/accumulate” with medium risk, a falling short‑term trend, and an expected 3‑month range roughly between $43 and $64. ^[52]
Intellectia labels CRSP a “Strong Buy candidate” based on 6 buy vs 4 sell technical signals and a short‑term uptrend, but its long‑term model projects an average price in the mid‑$40s in 2026 and lower still by 2030. ^[53]

The consistent theme: everyone agrees the stock will be volatile; they just disagree on which side of the coin you’ll land.

Macro & regulatory backdrop: the gene‑editing tide

CRISPR Therapeutics doesn’t operate in a vacuum; the whole gene‑editing field is in flux:

The FDA’s 2023–2025 approvals of CASGEVY and Bluebird’s Lyfgenia for sickle cell disease marked the first wave of gene‑editing and gene‑therapy approvals in hematology. ^[54]
Reports this autumn suggest the FDA is working on a streamlined approval framework for personalized gene‑editing therapies, potentially allowing umbrella trial designs and faster paths for rare variants — a key tailwind for companies like CRISPR. TS2 Tech
At the same time, competitors have hit speed bumps: Intellia paused dosing in a TTR amyloidosis trial after liver safety concerns, a reminder that on‑target doesn’t automatically mean off‑trouble when editing the liver. TS2 Tech+1
Big pharmas like AstraZeneca and Eli Lilly are buying into gene‑editing platforms, striking major partnerships and acquisitions, which indirectly validates the space’s long‑term relevance. TS2 Tech+1

For CRISPR Therapeutics, this ecosystem cuts both ways: rising regulatory comfort and big‑pharma interest boost the strategic value of its platform, but safety scares elsewhere can quickly compress valuations across the whole peer group.

Key catalysts to watch into 2026

A non‑exhaustive checklist for anyone following CRSP:

CASGEVY uptake and revenue trajectory
- Number of authorized treatment centers, cell collections and infusions quarter by quarter.
- Vertex’s CASGEVY revenue trajectory vs its >$100M 2025 guide and 2026 expectations.
CTX310 clinical milestones
- Detailed Phase 1 data (longer follow‑up, durability, any late safety signals).
- Design and early readouts from Phase 1b/2 in more common dyslipidemias.
Immuno‑oncology and autoimmune readouts
- Broader data sets for CTX112 in lymphoma and autoimmune disease and CTX131 in solid tumors and T‑cell lymphomas.
Pipeline expansion
- IND filings or first‑human trials for CTX320, CTX340, CTX450 and CTX460.
Financial path
- Quarterly burn versus CASGEVY & collaboration inflows, and use of the new ATM program.
M&A or strategic partnerships
- Any concrete move on the takeover front or large partnering deals around CTX310 or the in‑vivo platform.

Major risks: why this could still go sideways

This is high‑risk biotech, so the downside list is as important as the hype:

Science and safety risk
- Long‑term safety of in‑vivo editing (especially in the liver) remains under intense scrutiny; other CRISPR players have seen trial pauses and liver‑related adverse events.
Commercial execution
- CASGEVY’s slow, complex rollout — involving stem‑cell collection, high‑dose chemo, fertility concerns, and a $2M‑plus price tag — shows how hard it is to translate “functional cure” into scalable revenue.
Valuation risk
- GuruFocus pegs CRISPR’s price‑to‑sales ratio above 100x, with deeply negative margins and EPS around –$5.6. If CASGEVY underwhelms or CTX310 stumbles, that kind of multiple can compress brutally.
Competitive landscape
- Bluebird Bio (Lyfgenia), Vertex itself, Intellia, Editas, Verve and others are all pursuing overlapping indications, often with different technologies (viral vectors, base editing, siRNA). CRISPR must compete not just on efficacy but on safety, logistics and cost.
Takeover‑rumor whiplash
- If no deal emerges, or if any eventual offer comes in below the frothier expectations, the “M&A premium” could evaporate quickly.
Macro and policy risk
- Pricing pressure on ultra‑high‑cost therapies, changes to gene‑therapy reimbursement, or stricter long‑term safety requirements could materially alter economics for CASGEVY and future products.

Bottom line: what does all this mean for CRSP stock?

Put it together and CRISPR Therapeutics in December 2025 looks like a textbook high‑risk, high‑optionality biotech:

It already has the first CRISPR‑based therapy on the market.
It’s now shown convincing first‑in‑human data for a one‑shot cholesterol‑ and triglyceride‑lowering therapy that could open up a much larger market than rare blood diseases.
It holds nearly $2B in cash, giving it real runway to execute.
Wall Street, on average, thinks the stock should be worth more than today — but not by an order of magnitude, and with huge disagreement among analysts.
Takeover speculation adds a genuine but unpredictable kicker.

On the flip side, everything hinges on execution:

CASGEVY has to prove it can scale commercially in a messy real world.
CTX310 has to stay safe and effective as it moves into larger populations.
The company must eventually show a path from “science project” to durable, cash‑generating business in the face of fierce competition.

For risk‑tolerant investors who are comfortable with binary outcomes and sharp drawdowns, CRSP is one of the more interesting ways to express a view on gene editing becoming mainstream medicine. For more conservative investors focused on near‑term earnings and stable cash flows, the stock is probably better watched than owned.